Revenue · 2011–2025
Neurocrine Biosciences revenue
$2.9B+21.4% · FY2025
Neurocrine Biosciences (NBIX) reported $2.9B in revenue for fiscal 2025, +21.4% year on year.
| Fiscal year | Revenue | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $2.9B | +21.4% | Open → |
| FY20242024-12-31 | $2.4B | +24.8% | Open → |
| FY20232023-12-31 | $1.9B | +26.8% | Open → |
| FY20222022-12-31 | $1.5B | +31.3% | Open → |
| FY20212021-12-31 | $1.1B | +8.4% | Open → |
| FY20202020-12-31 | $1.0B | +32.7% | Open → |
| FY20192019-12-31 | $788M | +74.7% | Open → |
| FY20182018-12-31 | $451M | +179.2% | Open → |
| FY20172017-12-31 | $162M | +977.5% | Open → |
| FY20162016-12-31 | $15.0M | −24.1% | Open → |
| FY20152015-12-31 | $19.8M | +$19.8M | Open → |
| FY20142014-12-31 | $0 | −100.0% | Open → |
| FY20132013-12-31 | $2.9M | −94.5% | Open → |
| FY20122012-12-31 | $53.1M | −31.4% | Open → |
| FY20112011-12-31 | $77.4M | — | Open → |
Revenue — Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +29.4%
Revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Neurocrine Biosciences revenue |url=https://companiesranked.com/en/company/neurocrine-biosciences/revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Neurocrine Biosciences revenue. CompaniesRanked. https://companiesranked.com/en/company/neurocrine-biosciences/revenueBibTeX
@misc{companiesranked-en-company-neurocrine-biosciences-revenue-2026,
author = {{CompaniesRanked}},
title = {{Neurocrine Biosciences revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/neurocrine-biosciences/revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000914475-26-000007 · February 11, 2026
{{cite web |title=Neurocrine Biosciences revenue — 10-K (0000914475-26-000007) |url=https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-11}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.